Skip to main content

Table 1 Baseline characteristics of CRC patients in Fig. 1

From: CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

Group Number of Patients Age Sex TNM Stage Location CEA (ng/ml) CA199 (ng/ml) Diagnosis of Recurrence After Capecitabine Treatment
Capecitabine-sensitive 1 40 M II Rectum 1.9 0.6 No
2 62 M II Rectum 7.83 12.44 No
3 56 M II Colon 1.71 24.79 No
4 67 M II Colon 1.56 0.24 No
5 81 M II Rectum 4.06 19.04 No
6 32 F II Rectum 4 4.02 No
7 50 F II Rectum 3.31 15.57 No
8 62 F II Colon 2.41 3.57 No
9 52 M II Rectum 4.3 19.58 No
10 44 F II Colon 1.59 11.67 No
11 72 M II Colon 4.44 17.52 No
12 21 F II Colon 1.25 6.48 No
13 53 M II Rectum 1.06 20.42 No
14 63 M III Colon 0.8 16.51 No
15 43 M II Rectum 1.08 0.9 No
16 55 F II Rectum 1.18 4 No
17 46 M II Rectum 4.92 18.26 No
18 69 M II Rectum 0.89 23 No
19 70 F II Colon 4.28 8.01 No
20 71 F II Colon 4.62 20.58 No
21 64 F II Rectum 2.2 19.31 No
22 72 M II Rectum 1.19 2.28 No
23 61 F II Rectum 8.81 4.4 No
24 62 M II Rectum 1.92 28 No
25 50 F III Colon 3.65 16.42 No
26 65 M III Rectum 3.72 15.39 No
Capecitabine-resistant 27 63 M II Rectum 3.16 12.47 Yes
28 70 M III Colon 5.28 11.1 Yes
29 57 M III Colon 14.8 31.2 Yes
30 65 F II Rectum 3.65 29.4 Yes
31 52 M II Rectum 4.3 30.9 Yes
32 49 M III Rectum 25.8 36.8 Yes
33 54 M III Rectum 16.2 36.16 Yes
34 54 F III Rectum 29.74 53.2 Yes
35 45 F II Rectum 14 6.7 Yes
36 59 M II Colon 4.37 12.4 Yes